P A Reuken1, N Andreas2, P C Grunert1, S Glöckner3, T Kamradt2,4, A Stallmach1. 1. Jena University Hospital, Department of Internal Medicine IV, Jena, Germany. 2. Institute for Immunology, Jena University Hospital, Jena, Germany. 3. Institute for Medical Microbiology, Jena University Hospital, Jena, Germany. 4. Core Facility Cytometry, Jena University Hospital, Jena, Germany.
Abstract
BACKGROUND: Vaccination is a promising strategy to protect vulnerable groups like immunocompromised inflammatory bowel disease [IBD] patients from an infection with SARS-CoV-2. These patients may have lower immune responses. Little is known about the cellular and humoral immune response after a SARS-CoV-2 vaccination in IBD patients. METHODS: Totals of 28 patients with IBD and 27 age- and sex-matched healthy controls were recruited at Jena University Hospital. Blood samples were taken before, after the first, and in a subgroup of 11 patients after second dose of a SARS-CoV-2 vaccination. Cellular immune response, including IFN-γ and TNF-α response and antibody titres, were analysed. RESULTS: Overall, 71.4% of the IBD patients and 85.2% of the controls showed levels of anti-SARS-CoV-2 antibodies above the cutoff of 33.8 BAU/ml [p = 0.329] after the first dose. Even in the absence of SARS-CoV-2 antibodies, IBD patients showed significant T cell responses after first SARS-CoV-2 vaccination compared with healthy controls, which was not influenced by different immunosuppressive regimens. Associated with the vaccination, we could also detect a slight increase of the TNF production among SARS-CoV-2-reactive TH cells in healthy donorsn [HD] and IBD patients. After the second dose of vaccination, in IBD patients a further increase of humoral immune response in all but one patient was observed. CONCLUSIONS: Already after the first dose of a SARS-CoV-2 vaccination, cellular immune response in IBD patients is comparable to controls, indicating a similar efficacy. However, close monitoring of long-term immunity in these patients should be considered.
BACKGROUND: Vaccination is a promising strategy to protect vulnerable groups like immunocompromised inflammatory bowel disease [IBD] patients from an infection with SARS-CoV-2. These patients may have lower immune responses. Little is known about the cellular and humoral immune response after a SARS-CoV-2 vaccination in IBD patients. METHODS: Totals of 28 patients with IBD and 27 age- and sex-matched healthy controls were recruited at Jena University Hospital. Blood samples were taken before, after the first, and in a subgroup of 11 patients after second dose of a SARS-CoV-2 vaccination. Cellular immune response, including IFN-γ and TNF-α response and antibody titres, were analysed. RESULTS: Overall, 71.4% of the IBD patients and 85.2% of the controls showed levels of anti-SARS-CoV-2 antibodies above the cutoff of 33.8 BAU/ml [p = 0.329] after the first dose. Even in the absence of SARS-CoV-2 antibodies, IBD patients showed significant T cell responses after first SARS-CoV-2 vaccination compared with healthy controls, which was not influenced by different immunosuppressive regimens. Associated with the vaccination, we could also detect a slight increase of the TNF production among SARS-CoV-2-reactive TH cells in healthy donorsn [HD] and IBD patients. After the second dose of vaccination, in IBD patients a further increase of humoral immune response in all but one patient was observed. CONCLUSIONS: Already after the first dose of a SARS-CoV-2 vaccination, cellular immune response in IBD patients is comparable to controls, indicating a similar efficacy. However, close monitoring of long-term immunity in these patients should be considered.
Authors: Roya M Dayam; Jaclyn C Law; Rogier L Goetgebuer; Gary Yc Chao; Kento T Abe; Mitchell Sutton; Naomi Finkelstein; Joanne M Stempak; Daniel Pereira; David Croitoru; Lily Acheampong; Saima Rizwan; Klaudia Rymaszewski; Raquel Milgrom; Darshini Ganatra; Nathalia V Batista; Melanie Girard; Irene Lau; Ryan Law; Michelle W Cheung; Bhavisha Rathod; Julia Kitaygorodsky; Reuben Samson; Queenie Hu; W Rod Hardy; Nigil Haroon; Robert D Inman; Vincent Piguet; Vinod Chandran; Mark S Silverberg; Anne-Claude Gingras; Tania H Watts Journal: JCI Insight Date: 2022-06-08
Authors: Johanna Maria Classen; Anna Muzalyova; Sandra Nagl; Carola Fleischmann; Alanna Ebigbo; Christoph Römmele; Helmut Messmann; Elisabeth Schnoy Journal: Dig Dis Date: 2021-12-10 Impact factor: 2.404
Authors: James L Alexander; Nicholas A Kennedy; Hajir Ibraheim; Sulak Anandabaskaran; Aamir Saifuddin; Rocio Castro Seoane; Zhigang Liu; Rachel Nice; Claire Bewshea; Andrea D'Mello; Laura Constable; Gareth R Jones; Sharmili Balarajah; Francesca Fiorentino; Shaji Sebastian; Peter M Irving; Lucy C Hicks; Horace R T Williams; Alexandra J Kent; Rachel Linger; Miles Parkes; Klaartje Kok; Kamal V Patel; Julian P Teare; Daniel M Altmann; Rosemary J Boyton; James R Goodhand; Ailsa L Hart; Charlie W Lees; Tariq Ahmad; Nick Powell Journal: Lancet Gastroenterol Hepatol Date: 2022-02-04
Authors: Ainsley Ryan Yan Bin Lee; Shi Yin Wong; Louis Yi Ann Chai; Soo Chin Lee; Matilda Xinwei Lee; Mark Dhinesh Muthiah; Sen Hee Tay; Chong Boon Teo; Benjamin Kye Jyn Tan; Yiong Huak Chan; Raghav Sundar; Yu Yang Soon Journal: BMJ Date: 2022-03-02
Authors: Richard Vollenberg; Phil-Robin Tepasse; Joachim Ewald Kühn; Marc Hennies; Markus Strauss; Florian Rennebaum; Tina Schomacher; Göran Boeckel; Eva Lorentzen; Arne Bokemeyer; Tobias Max Nowacki Journal: Biomedicines Date: 2022-01-13